[{"orgOrder":0,"company":"Indication BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"||HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Indication BioScience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indication BioScience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Indication BioScience \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Indication BioScience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : The U.S. Patent covers pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis.

Product Name : Atrova+

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 02, 2021

Lead Product(s) : Atorvastatin,Cannabidiol

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Preclinical

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank